Dr. Colin Doherty:

I would not say there are many. It is the most recent ones. Vigabatrin is a good example of a drug where we came across the problem five years after the start. There is a definite concern about that, even with the newer drugs.

At a minimum, one needs to go through several thousand patients treated, using proper observation of those thousands of patients. We can say with Fycompa, this new drug, that we have had several thousand patients but it has only been on the market two years. We are all being very cautious about the use of the drug because we know the stories about vigabatrin and we are keeping a very open mind, but we are dealing with patients who are looking for life-saving treatment. We are constantly aware of that.